Bibliographic Details
| Title: |
Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region. |
| Authors: |
Alnaqbi, Khalid A.1,2 (AUTHOR) kalnaqbi@gmail.com, Al Adhoubi, Nasra3 (AUTHOR), Aldallal, Sara4,5 (AUTHOR), Al Emadi, Samar6 (AUTHOR), Al-Herz, Adeeba7 (AUTHOR), El Shamy, Amin M.8 (AUTHOR), Hannawi, Suad9 (AUTHOR), Omair, Mohammed A.10 (AUTHOR), Saad, Sahar A.11 (AUTHOR), Kvien, Tore K.12,13 (AUTHOR) |
| Source: |
BioDrugs. May2024, Vol. 38 Issue 3, p449-463. 15p. |
| Subject Terms: |
*PSORIATIC arthritis, *BIOSIMILARS, *MEDICAL personnel, *ARTHRITIS, *RHEUMATOID arthritis, *SPONDYLOARTHROPATHIES |
| Geographic Terms: |
PERSIAN Gulf |
| Abstract: |
Background: Though biologic agents have significantly improved the treatment of inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis), high costs, stringent regulations, strict reimbursement criteria, and existing patents have limited patient access to treatments. While being highly similar in quality, safety, and efficacy to biologic reference products, biosimilars can reduce the financial burden and prevent underutilization of medication. Objective: The objective of this initiative was to develop an evidence-based consensus of overarching principles and recommendations aimed at standardizing the use of biosimilars in treating inflammatory arthritis in the Gulf region. Methods: A task force of practicing rheumatologists, a clinical pharmacist, a health economist, patients, regulators, and payors from across the Gulf region developed recommendations and overarching principles based on the outputs of a systematic literature review conducted to address Patient-Intervention-Comparison-Outcome (PICO) questions specific to key challenges regarding the use of biosimilars for the treatment of inflammatory arthritis in the region. As the data before 2017 have been previously reviewed in another publication, the current review focused on data published between January 2017 and August 2022 (PROSPERO ID CRD42022364002). Consensus on each statement required a level of agreement of 70% or greater. Results: Consensus was reached for five overarching principles and nine recommendations by the task force. The principles emphasize the importance of improving the awareness, understanding, and perception of biosimilars, as well as the need for regulated regional real-world data generation and protocols to make biosimilars a viable and affordable treatment option for all patients. The consensus recommendations advocate the need for shared treatment decisions between rheumatologists and patients when considering biosimilars. They further recommend that confirmation of a biosimilar's efficacy and safety in a single indication is sufficient for extrapolation to other diseases for which the reference product has been approved. Finally, there is a need for pharmacovigilance and national health policies governing the adoption and prescription of biosimilars in clinical practice across the region. Conclusions: These are the first consensus recommendations for the Gulf region based on a systematic literature review and Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines, integrating clinical evidence with clinical expertise to optimize decision making for the use of biosimilars in patients with inflammatory arthritis. They were formulated based on predominantly international data because of the limited regional data and therefore can be generalized to serve as recommendations for healthcare professionals in other parts of the world. [ABSTRACT FROM AUTHOR] |
|
Copyright of BioDrugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
